CARE Faculty Perspectives from ESMO:
Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976) 
Presenter: S. Hurvitz (UCLA School of Medicine, Internal Medicine/Div of Heme-Onc, Los Angeles, USA)

Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial. 
Presenter: J. Baselga

 

We would like to thank Dr. Sunil Verma for live tweets during conference sessions at ECCO-ESMO 2011

Bolero-2: Everolimus in combination with exemestane for advanced breast cancer - Phase III trial #emcc2011
BOLERO-2: Significant improvement in Progression Free Survival ( PFS 2.8 m 6.9 m HR -.43 P=highly significant. Very striking! #emcc2011
BOLERO-2: Does this change our standard of care for metastatic HR+ breast cancer...very likely. Still need to await mature data #emcc2011
BOLERO-2: Dr. Fabrice Andre: Everolimus in HR+ve Breast Cancer represents one of the biggest advances in medical oncology #emcc2011

Sorafenib in MBC - no improvement in PFS or TTP. Trend of better PFS with placebo in the Letrozole arm. Data for OS is immature #emcc2011
A Randomized Phase IIb Study of Sorafenib (SOR) vs Placebo (PL) in Combination with Docetaxel And/or Letrozole in (MBC) #emcc2011

Phase II study shows new cancer drug comb. significantly delays breast cancer progression (embargo lifted) http://stockholm2011.ecco-org.eu/Global/News/News/2011/09/Phase-II-study-shows-new-cancer-drug-combination-significantly-delays-breast-cancer.aspx #emcc2011

TAMRAD Phase 2 GINECO Trial Comparing Tamoxifen (TAM) Plus Everolimus (RAD) With TAM Alone in Patients #emcc2011
TAMRAD Results: Tam vs. Tam +Everolimus (mandated previous AI use) : CBR 61 vs 42% , TTP HR 0.54 Survival 0.45. Significant benefit seen
TAMRAD Results: Tam vs. Tam +Everolimus MBC Trial: CBR 61 vs 42% , TTP HR 0.54 Survival 0.45. Significant benefit seen #emcc2011

PHASE II STUDY of T-DM1 (Antibody drug conjugate) vs. Trasuzumab + Docetaxel (n=137): PFS T-DM1 14.2m D+T 9.2m HR 0.594 #emcc2011
Phase II Study of T-DM1 vs T +Docetaxel: Grade 3 and 4 toxicity – 89.4% with T+D vs T-DM1 n=46.4%. #emcc2011
PHASE II STUDY of T-DM1 (Antibody drug conjugate) vs. Trasuzumab + Docetaxel (n=137): PFS T-DM1 14.2m D+T 9.2m HR 0.594

Randomized Phase II Study of Gem+Cis vs. Gem +Cis with Iniparib (Cycle Arrest agent) #emcc2011

PROBLEM WITH THE ABIGAIL STUDY IS THAT BOTH ARMS RECEIVE BEV – hard to evaluate predictive value when you don’t have a Bev naïve control arm
ABIGAIL: VEGFA – was the only biomarker that was predictive of PFS (HR 1.57)#EMCC2011